Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind, randomized, placebo controlled, multi-center, multi-nation, clinical trial of JadiCell™ Universal Donor Stem Cell Drug in the patients with COVID-19 associated lung failure

Next Previous
Trial Profile

A double-blind, randomized, placebo controlled, multi-center, multi-nation, clinical trial of JadiCell™ Universal Donor Stem Cell Drug in the patients with COVID-19 associated lung failure

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 20 Sep 2022 According to a Therapeutic Solutions International media release, the company entered into an agreement with GHS Investments, LLC to purchase up to $10,000,000 of Registered Common Stock to secure financing to complete this study.
  • 25 Aug 2022 According to a Therapeutic Solutions International media release, the company has announced filing with the Food and Drug Administration (FDA) an amendment to the trial requesting expansion of eligible patients with all patients suffering from Acute Respiratory Distress Syndrome (ARDS) regardless of cause.
  • 18 Jul 2022 According to a Therapeutic Solutions International media release, company announced granting of Emergency IND # 28685 and a May Proceed Notification from the Food and Drug Administration (FDA) for the treatment of advanced COVID-19 ARDS outside

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top